SK Bioscience has revealed that 99-percent of participants for phases 1 and 2 of its COVID-19 vaccine clinical trials formed antibodies against the virus.
On Friday, the company said that results from both trials showed success after administering doses to 328 participants.
It added that there were no signs of serious adverse effects to the vaccine.
Currently, the company has already begun phase 3 of the trials in South Korea and Vietnam and is waiting to start in other countries in Southeast Asia and Europe.
The announcement added the result is a step closer to having South Korea's first domestically developed vaccine.